Therapy based on immune checkpoint blockade (ICB) targets T cell inhibitory receptors such as programmed cell death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4), thus leading to activation of tumour-specific T cells. The gene discussed is CTLA4; the disease is neoplasm.